Payment overview · 2025
General Payments
$2,832.25
154 reported records · 32 companies
Healthcare provider profile · identity verified
Thomas Daniel Ade, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOLINE, IL · NPI 1568448884
Verified facts
What the public records show
CMS Open Payments records show Thomas Daniel Ade, MD received $2,832.25 in general payments during 2025 across 154 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ofev, Ozempic, Paxlovid, Synthroid, Tezspire, Trelegy Ellipta, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Tezspire by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 516 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ofev by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 516 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $373.65 | 13.2% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $273.26 | 9.7% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.58 | 9.6% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $214.79 | 7.6% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $188.50 | 6.7% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $170.56 | 6.0% | 11 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $165.84 | 5.9% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $129.82 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.20 | 4.0% | 6 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $112.15 | 4.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $98.61 | 3.5% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $96.40 | 3.4% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $79.99 | 2.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.84 | 2.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.20 | 2.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $49.68 | 1.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.96 | 1.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.68 | 1.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.13 | 1.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.93 | 1.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.46 | 1.0% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $23.87 | 0.8% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $22.54 | 0.8% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $21.64 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.87 | 0.7% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $20.31 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.62 | 0.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.48 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.44 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.37 | 0.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.07 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.81 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,798.25 | 153 |
| Education | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $247.31 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $216.92 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.95 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.74 | 8 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $165.84 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.70 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $164.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $148.83 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.02 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $133.55 | 7 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $129.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.85 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.06 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $106.35 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $104.83 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $98.61 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $96.40 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $85.80 | 12 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $79.99 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $79.86 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.85 | 4 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $73.66 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.20 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $51.50 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.68 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.49 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $5.90 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $5.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 377 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 516 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 394 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
516 | 142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
377 | 97 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
394 | 117 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
516 | 142 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
377 | 97 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1209 | 356 |
| Lisinopril | Lisinopril | 844 | 245 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 762 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 665 | 184 |
| Metoprolol Succinate | Metoprolol Succinate | 659 | 186 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 656 | 261 |
| Jardiance | Empagliflozin | 516 | 142 |
| Gabapentin | Gabapentin | 444 | 131 |
| Furosemide | Furosemide | 436 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 144 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 394 | 117 |
| Eliquis | Apixaban | 377 | 97 |
| Omeprazole | Omeprazole | 377 | 110 |
| Metformin Hcl | Metformin Hcl | 354 | 111 |
| Tramadol Hcl | Tramadol Hcl | 348 | 85 |
| Prednisone | Prednisone | 337 | 169 |
| Simvastatin | Simvastatin | 323 | 91 |
| Losartan Potassium | Losartan Potassium | 318 | 102 |
| Potassium Chloride | Potassium Chloride | 295 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 87 |
| Meloxicam | Meloxicam | 282 | 71 |
| Ezetimibe | Ezetimibe | 279 | 84 |
| Alprazolam | Alprazolam | 278 | 81 |
| Allopurinol | Allopurinol | 255 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 84 |
| Irbesartan | Irbesartan | 234 | 72 |
| Sertraline Hcl | Sertraline Hcl | 234 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 68 |
| Glimepiride | Glimepiride | 227 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 79 |
| Spironolactone | Spironolactone | 216 | 55 |
| Trazodone Hcl | Trazodone Hcl | 205 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 58 |
| Doxycycline Hyclate | Doxycycline Hyclate | 177 | 144 |
| Montelukast Sodium | Montelukast Sodium | 163 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 45 |
| Ibandronate Sodium | Ibandronate Sodium | 146 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 140 | 33 |
| Lorazepam | Lorazepam | 134 | 35 |
| Carvedilol | Carvedilol | 132 | 48 |
| Spiriva Respimat | Tiotropium Bromide | 131 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 27 |
| Ozempic | Semaglutide | 119 | 29 |
| Clonazepam | Clonazepam | 118 | 23 |
| Donepezil Hcl | Donepezil Hcl | 118 | 29 |
| Warfarin Sodium | Warfarin Sodium | 114 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 110 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 108 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 96 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 39 |
| Azithromycin | Azithromycin | 93 | 60 |
| Breo Ellipta | Fluticasone/Vilanterol | 93 | 23 |
| Famotidine | Famotidine | 90 | 30 |
| Valsartan | Valsartan | 85 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 82 | 24 |
| Alendronate Sodium | Alendronate Sodium | 79 | 28 |
| Rybelsus | Semaglutide | 79 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 23 |
| Finasteride | Finasteride | 75 | 20 |
| Pregabalin | Pregabalin | 75 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 21 |
| Atenolol | Atenolol | 70 | 24 |
| Celecoxib | Celecoxib | 70 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 53 |
| Linzess | Linaclotide | 64 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 55 |
| Mirtazapine | Mirtazapine | 60 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 58 | 16 |
| Nifedipine Er | Nifedipine | 58 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 57 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 18 |
| Levofloxacin | Levofloxacin | 54 | 47 |
| Naproxen | Naproxen | 54 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 38 |
| Myrbetriq | Mirabegron | 52 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 51 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 48 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Kerendia | Finerenone | 47 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 47 | 16 |
| Torsemide | Torsemide | 47 | 19 |
| Cefuroxime | Cefuroxime Axetil | 46 | 28 |
| Memantine Hcl | Memantine Hcl | 46 | 12 |
| Glipizide | Glipizide | 45 | 16 |
| Lansoprazole | Lansoprazole | 45 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 18 |
| Entresto | Sacubitril/Valsartan | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 43 | 12 |
| Methimazole | Methimazole | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Amoxicillin | Amoxicillin | 42 | 30 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Ofev | Nintedanib Esylate | 41 | suppressed |
| Tezspire | Tezepelumab-Ekko | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | 12 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 13 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Repatha Syringe | Evolocumab | 37 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 14 |
| Digoxin | Digoxin | 36 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 36 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 36 | suppressed |
| Fluocinonide | Fluocinonide | 35 | 14 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Temazepam | Temazepam | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Lovastatin | Lovastatin | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 27 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 27 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 21 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 12 |
| Fluconazole | Fluconazole | 26 | 19 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 19 |
| Nexletol | Bempedoic Acid | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 13 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,832.25 · 154 records | AstraZeneca Pharmaceuticals LP | ACTHAR, AIRSUPRA, AUSTEDO XR, Arikayce, BREZTRI, CAMZYOS, CAPLYTA, CREON, CUVITRU, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EVENITY, FARXIGA, FASENRA, FREESTYLE LIBRE 3, Hillrom - Cardiac Ambulatory Monitor, Hillrom - Vest System Model 105 Home Care, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, LINZESS, Leqembi, MOUNJARO, NUCALA, NURTEC ODT, OFEV, Ohtuvayre, Ozempic, PAXLOVID, Prolastin-C Liquid, QULIPTA, REXULTI, SHINGRIX, SYNTHROID, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VERQUVO, VRAYLAR, VYNDAMAX, VYNDAQEL, WAKIX, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error